We have studied the outcome of 21 1 consecutive unrelated donor (URD) bone marrow transplants (BMT) performed at the University of Minnesota (Minneapolis, MN) between May 1985 and December 1992. Ninety patients (43%) received marrow matched serologically at HLA A, B, and DR loci; 86 (4190) received marrow with a major and 32 (15%) marrow with a minor serologic mismatch at the HLA A or B locus. Multivariate analysis revealed that older age had an adverse effect on survival. In younger (age less than 18 years) recipients, survival after fully matched (A, B, and DR subtype) or major mismatched (A or B locus), DR subtypematched donor BMT was not significantly different (P = .4; survival: 53% Y 41%. respectively, at 3 years). For adults,
B
ONE MARROW transplantation (BMT) is an accepted treatment for a variety of hematologic malignancies, bone marrow failure syndromes, immunodeficiencies, and metabolic disorders.'" An HLA-matched related donor (RD) is available for fewer than 35% of potential recipients; for patients without RDs, the use of an unrelated donor (URD) is an alternative. Establishment of an international network of URD registries working in close cooperation has facilitated identification of suitable donors, but a fully matched URD is located for a minority of ~atients. 4 .~ Previous reports of URD BMT have focused on the use of fully serologically matched donors, although a multicenter study has described the use of mismatched donors.'"" The degree of histoincompatibility that can be tolerated remains to be defined. Here we analyze results of 21 1 consecutive URD BMTs performed in both children and adults at a single institution. A large proportion of these patients received marrow with a serologic HLA mismatch, and approximately half were children, allowing us to make unique observations of the effect of age and HLA histoincompatibility on outcome of URD BMT. 
PATIENTS AND METHODS
We analyzed outcomes of 21 1 consecutive URD BMTs performed at the University of Minnesota (Minneapolis, MN) between May 1985 and December 1992. URD BMTs were performed as therapy for a variety of hematologic malignancies, immune deficiencles, metabolic disorders, or other marrow failure states. Patient characteristics, treatment protocols, and graft-versus-host disease (GVHD) prophylaxis are described in Table 1 . Patients with high-risk acute lymphoblastic leukemia (ALL) in first remission were eligible for URD BMT, including patients with hypodiploid ALL, patients with t(4; 11) and t(9; 22), and patients who did not achieve remission within 28 days of induction therapy. Patients with acute myeloid leukemia in first remission were eligible for transplant if they were considered at high risk on the basis of cytogenetics [ie, patients with translocations t(8;21) or t( IS; 17) or 16q abnormality, which indicate a favorable prognosis with conventional treatment, were not eligible/. Identical treatment and support protocols were used regardless of age, under the auspices of a combined adult and pediatric BMT program. Ages ranged from less than 1 year to 49 years. All patients or their guardians signed informed consent approved by the Committee on the Use of Human Subjects in Research at the University of Minnesota.
URD Selection
Potential URDS were located through a network of national and international bone marrow donor registries as previously described?,' Patients and donors were typed for HLA A and B using serologic techniques identifying all World Health Organization (WHO)-recognized specificities current at the time of transplant. All but S of the 21 1 pairs were typed for DR by DNA techniques either prospectively or retrospectively. Of these five pairs, two had serologic DR typing only, the Dw typing by homozygous typing cells (HTCs) being uninterpretable; in these cases, HLA typing was considered incomplete, and these patients were excluded from analyses involving HLA matching. Three pairs had serologic DR typing and Dw typing by HTCs: one of these patients was DR subtype-mismatched.
Seventy-three patients (35%) received URD marrow serologically matched at HLA A and B, and were DR subtype-identical. Seventeen patients (8%) received marrow serologically matched at HLA A and B, but with a single DR subtype mismatch. Thirty-two patients ( I 5 % ) received marrow with a single minor serologic HLA mismatch, that is, a mismatch within a serologically crossreactive group at the HLA A or B locus as defined by the National Marrow Donor Program." HLA DlSPARllY IN UNRELATED DONOR BMT Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; TBI, total body irradiation; ATG, antithymocyte globulin; AraC, cytosine arabinoside.
Retrospectively, 4 of these 32 were found to have an additional DR subtype mismatch and were excluded from analysis of the effect of minor mismatch on outcomes.
Eighty-six patients (41%) received marrow with a major serologic mismatch, that is, a mismatch occurring between serologically noncrossreactive groups at the HLA A (n = 51) or B (n = 35) locus. Retrospectively, 6 of these 86 were found to have an additional DR subtype. mismatch and were excluded from analysis of HLA matching. One patient received marrow with a major and a minor serologic HLA mismatch and was also excluded from analyses involving HLA matching.
Analysis of Outcome in 21 I URD BMT Recipients
The clinical and laboratory data were retrieved from the University of Minnesota BMT Database, which systematically and prospectively collects data on consecutive transplanted patients. Patients with chronic myelogenous leukemia (CML) in accelerated phase or in stable phase after blast crisis, patients with acute leukemia beyond the first complete remission, and patients with myelodysplastic syndrome were considered to be poor-risk patients; all other diagnostic groups were considered to be good risk. GVHD was diagnosed and graded by standard criteria.13 Incidences and 95% confidence intervals of survival, engraftment, GVHD, and relapse were determined using the Kaplan-Meier and Peto-Wilc~xon'~"~ methods.
Comparison of outcomes in different patient groups were made using the logrank test.'' The Cox proportional hazards model was used to perform multivariate analyses determining the independent effect of variables. Factors tested in the model included age, disease, disease stage, interval from diagnosis to transplant, donor-recipient HLA matching status, development of GVHD, GVHD prophylaxis, CMV status, and donor-recipient sex matching on outcome of URD BMT.'* Only factors that influenced risk were retained in final models.
Comparison of URD and RD BMT
To identify differences in outcome attributable to the use of an URD, URD recipients were paired with genotypically HLA-matched sibling RD recipients transplanted by our program according to diagnosis, disease stage, recipient age (by decade), and year of transplant (within 2 years). Using these criteria, RD controls were found for 142 URD recipients, and characteristics of these 284 patients are shown in Table 2 . Suitable RD controls were not available for the remaining 69 URD recipients, who are, therefore, not included in this analysis. Kaplan-Meier estimates were used to determine and compare the incidence of various endpoints in the URD and RD groups as described earlier. In the comparison of URD recipients with their RD controls, "mismatched" marrow refers to patients receiving marrow with a major serologic mismatch at the HLA A or B locus; "matched" refers to all other patients.
Assessment of Quality of Life
Quality of life was assessed by several methods in URD recipients surviving for greater than 2 years (n = 39). URD recipients were each matched with one (n = 8) or two (n = 31) RD recipients also surviving at least 2 years, according to patient age and year of transplant (within 2 years). Patients (or parents in the case of children under 18 years) were contacted by trained telephone interviewers using a standardized questionnaire. The questionnaire was modified from the medical outcomes study (MOS) short-form general health survey, largely as described by Wingard et aI.'7.1R Subjects were asked to rate their overall health on a scale from poor to excellent (1 to 5). Respondents were asked to indicate their level of physical functioning on a seven-step Kamofsky scale (40% to 1o0%).l9 Physical functioning was rated to describe the degree to which health limited various daily activities. Responses ranged from 3 ("not at all") to 2 ("for less than 3 months") to 1 ("more than 3 months").
Social functioning was evaluated by a six-point rating of how much time during the past month the respondents felt that their health had limited their social activities, "like visiting with friends or close relatives." Answers ranged from 1 ("all of the time") to 6 ("none of the time"). Health perception was assessed by asking respondents to rate items such as "I am somewhat ill" and "I have been feeling bad lately" on a scale of 1 ("definitely true") to 5 ("definitely false").
The survey was completed for 31 URD recipients and their RD controls (n = 53). The remaining URD recipients were excluded because of inability to locate the patient (n = 3) and failure to identify and interview at least one control (n = 5 ) (Table 3) . Other factors including disease stage, interval from diagnosis to transplant, occurrence of grade 3 to 4 acute GVHD, and diagnosis were not independently associated with poorer survival.
RESULTS

Outcomes in 211 URD
The important influence of recipient age and HLA matching on outcome is shown in Fig 1. In patients aged less than 18 Statistical testing for the interaction between age and HLA matching status, however, was not significant, probably due to small sample size.
To further explore the effects of HLA matching, outcomes in groups of patients with different degrees of HLA disparity were compared with a reference group of 73 patients who were HLA A, B, and DR subtype-matched (fully matched group; Table 4 ). In a univariate analysis, survival is superior in the fully matched group compared with survival in patients receiving marrow with a major or a minor mismatch or with a DR subtype mismatch. Outcomes are similar in patients receiving marrow with a minor or a Fajor mismatch at class l loci. After completion of multivariate analysis, mortality is increased by 50% in recipients of marrow with a major HLA mismatch ( P = .06). A nonsignificant increase in mortality was seen in recipients of marrow with a DR subtype mismatch (relative risk
[RR], 1.3; P = S ) and in recipients of marrow with a minor mismatch (RR, 1.2; P = S ) . This estimate is based on a small number of patients and should be interpreted with caution. Acute and chronic GVHD. The overall incidence of grade 2 to 4 acute GVHD in the URD recipients was 0.64. The incidence of grade 2 to 4 acute GVHD was 0.56 (95% CI, 0.45 to 0.67) for children (aged less than 18 years) and 0.72 (95% CI, 0.62 to 0.82) for adults (aged 2 18 years; P = .04). Other factors including donor-recipient €LA matching (Table 4) , donor or recipient gender, or recipient CMV status before transplant did not significantly influence the incidence of acute GVHD.
The incidence of extensive chronic GVHD for the 21 1 patients was 53% at l year. Multivariate analysis revealed that increasing recipient age (RR, 6.3 for patients aged 40 to 49 years v patients aged 0 to 10 years; P < .Ol), but not other patient characteristics, had an independent, adverse effect on the incidence of extensive chronic GVHD in the entire series.
Analysis of 142 URD and RD Pairs
To refine this assessment of the clinical impact of an URD, we have compared the outcome of 142 URD and 142 RD transplants. URD and RD pairs were individually matched for diagnosis, stage of disease, age, and year of transplant.
Survival. Survival in the URD group was 0.31 (95% CI, 0.23 to 0.39), while that in the RD group was 0.51 (95% CI, 0.42 to 0.60) at 3 years ( P = .0001). Early posttransplant mortality was high in the URD group compared with the RD group, with 6-month survival of 0.45 (95% CI, 0.37 to 0.53) versus 0.67 (95% CI, 0.59 to 0.74), respectively. In multivariate analysis, the difference in survival between URD and RD BMT is still apparent after adjusting for the occurrence of grades 2 to 4 GVHD (RR of death after URD BMT, 1.9; 95% CI, 1.4 to 2.6; P = .OOOl). This suggests that the excess mortality in the URD group is not due only to the increased rate of GVHD. Importantly, survival in recipients of URD marrow without a major HLA match and their RD controls is 0.38 versus 0.52 ( P = .17) at 3 years, while excess mortality was frequent in HLA A or B majormismatched URD recipients versus their RD control groups (3-year survival, 0.26 v 0.52; P = .00001; Fig 2) .
A possible confounding variable in the comparison of these patient groups is the time from diagnosis to transplant, as a search for a suitable URD can be lengthy. The addition of time to transplant as a covariate in a Cox model of survival did not alter the estimate of the effect of donor type (data not shown), indicating that the prolonged search time and selection bias in URD is insufficient to explain the excess mortality in this group.
GVHD. Acute GVHD, grades 2 to 4, was more frequent in the URD than the RD pairs, (RR, 1.3; 95% CI, 1.0 to 1.7; P = .03). The incidence of extensive chronic GVHD is also higher in the URD than the RD group (57% [95% CI, 45% to 69%] v 43% [95% CI, 33% to 53%]; P = .12), but this difference is not statistically significant. Malignant relapse. Among 234 patients with hematologic malignancy, the incidence of relapse in the URD group was significantly lower than in the RD group ( P = .03; Fig  3) . In multivariate analysis after adjustment for acute GVHD grades 2 to 4, the decreased relative risk of relapse associated with an URD remains (RR 0.4, P = .04). Comparison of relapse rate in these patient populations is complicated by a high early death rate in URD recipients, resulting in fewer URD recipients at risk of relapse over time. To address this issue, we have compared the incidence of relapse in URD and R D patients up through 1 year after BMT and separately in patients who survived beyond 1 year. Within the first year after BMT, we observed a lower incidence of relapse in the URD group (3%) than in R D counterparts (13%; P = .003).
Similarly, a lower incidence of relapse was observed in the URD group surviving for greater than 1 year (4%) than in their RD counterparts (17%; P = .06).
Quality of Life
Thirty-one URD and 52 RD BMT recipients matched for age and year of transplant and surviving at least 2 years from BMT were interviewed regarding their quality of life. Interviews addressed both the patients' subjective perceptions of their own health and performance and objective measures of physical and social functioning. A standard selfassessed Karnofsky score was also obtained.
RD and URD recipients generally judged their quality of life to be good, with only one URD recipient and six R D recipients reporting being unable to perform normal activities (Karnofsky score of 70% or less; Table 5 ). Only two RD and no URD recipients had been limited for more than 3 months in any of the physical activities questioned (sports, carrying groceries, walking uphill, bending and lifting, walking one block, and personal hygiene). Ninety percent of URD recipients and 77% of RD recipients were limited in their social activities "a little of the time" or "none of the time," with only two RD recipients and no URD recipients reporting being limited "all of the time." The majority of URD (n = 29) and RD (n = 49) recipients described their general health as "good," "very good," or "excellent,"
with two URD and two RD recipients rating their health as "fair" and two RD recipients rating their health as "poor."
Overall, there were no significant differences between the URD and the RD recipients in their self-reported quality of life, although there was a trend ( P = .09) to a higher global health statement score (a measure of subjective well-being)
in the URD recipients.
Of the 31 URD recipients, 28 were working full-time or attending school at a level appropriate for their age. Two URD recipients were not working by choice, and one URD recipient remained unemployed as a consequence of his illness. Seventeen URD recipients reported their illness had no effect on their job plans, while nine patients reported a sizable or great effect on job plans.
DISCUSSION
This analysis demonstrates that for the whole URD BMT group, older age and HLA A or B serologic mismatch have independent and adverse effects on survival after URD BMT.
In younger patients, serologic major mismatch at the HLA A or B locus is compatible with a good outcome, though the trend is toward decreased survival when compared with recipients of fully matched marrow. Adults receiving HLA serologically major-mismatched marrow have significantly decreased survival compared with those receiving matched marrow. These data suggest that for younger URD BMT candidates, the search for a donor can be broadened considerably to include individuals with HLA major serologic mismatch at the A or B locus. Use of URD donors with a major HLA serologic mismatch for adult recipients, however, adversely affects survival and should be reserved for situations in which no reasonable alternative therapy is available. We recommend that major HLA-mismatched marrow is not used in recipients over 40 years, except in the context of a clinical trial to evaluate new approaches to management of GVHD (1) (2) (3) (4) (5) (6) .8
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and regimen-related toxicity. In this study, use of marrow with a minor serologic mismatch was associated with similar outcomes in univariate analysis as use of marrow with a major serologic mismatch. However the number of patients receiving minor mismatched marrow was too small to allow a robust analysis of the impact of this disparity on outcome, and larger studies are needed to answer this question. Paired analysis of 142 URD recipients with comparable RD recipients transplanted under similar conditions allows us to make some unique observations concerning outcome of URD BMT. Comparison of URD recipients of fully serologically HLA-matched marrow with their RD controls does not show a significant survival difference. The increased mortality relative to RD recipients occurs chiefly in recipients of URD marrow with a major HLA A or B mismatch. These data are concordant with the findings of Beatty et al,7 who compared survival of 52 fully HLA-matched URD recipients with paired RD recipients and found no difference in relapse-free survival. This finding suggests that at least a proportion of the excess mortality associated with URD BMT in older patients is directly related to histocompatibility differences at the HLA A and B loci that can be identified by serology.
Acute GVHD was more frequent in the URD recipients. However, the difference in survival between URD and RD was still apparent after controlling for the excess GVHD in a multivariate analysis, suggesting that acute GVHD is at least not the sole cause of the increased mortality. The incidence of extensive chronic GVHD was not significantly higher in the URD recipients compared with RD recipients, a finding on which previous reports of smaller patient groups have ~aried.'~'~ It has been hypothesized that URD BMT may decrease the risk of relapse.6 Paired analysis allows us to demonstrate for the first time that URD BMT confers an increased degree of protection from relapse not observed in RD recipients. Among patients with hematologic malignancy, the incidence of relapse is significantly lower in the URD group than in the RD group. This finding may indicate that URD BMT generates a more potent graft-versus-leukemia (GvL) effect than RD BMT.2'.22 Prolonged follow up of larger numbers of patients is needed to confirm these observations. Interestingly, measurement of quality of life both by traditional Karnofsky assessment and newer approaches in URD and RD recipients surviving greater than 2 years demonstrates equivalent, satisfactory quality of life. Previous reports have suggested impaired quality of life earlier in the posttransplant period for URD BMT recipient^.^.'^ The data reported in this study demonstrate that although early convalescence may be prolonged, long-term survivors of URD can expect a quality of life that returns to normal or near normal levels in the majority of cases and that does not differ from the vast experience accumulated in the RD ~etting.'~.'~ Such information will be particularly helpful in counseling URD candidates.
